Federated Hermes Inc. Has $40.22 Million Stake in Insulet Co. (NASDAQ:PODD)

Federated Hermes Inc. raised its holdings in Insulet Co. (NASDAQ:PODD) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,347 shares of the medical instruments supplier’s stock after acquiring an additional 10,883 shares during the quarter. Federated Hermes Inc.’s holdings in Insulet were worth $40,217,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd lifted its stake in shares of Insulet by 227.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after purchasing an additional 268,553 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Insulet by 119.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after acquiring an additional 43,147 shares during the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Insulet by 33.7% in the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after acquiring an additional 9,240 shares in the last quarter. Graham Capital Management L.P. raised its stake in shares of Insulet by 689.8% in the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock valued at $3,683,000 after acquiring an additional 20,171 shares in the last quarter. Finally, Aquila Investment Management LLC acquired a new stake in Insulet in the 4th quarter worth approximately $1,302,000.

Insider Activity

In other news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.90% of the company’s stock.

Insulet Trading Up 0.9 %

Shares of PODD opened at $166.25 on Friday. The stock’s 50-day moving average price is $173.97 and its 200 day moving average price is $178.81. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $335.91. The firm has a market capitalization of $11.64 billion, a price-to-earnings ratio of 57.13, a P/E/G ratio of 2.97 and a beta of 0.98.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. The business had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. Insulet’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 earnings per share. As a group, research analysts predict that Insulet Co. will post 3.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Barclays lowered their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Stifel Nicolaus raised their target price on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Piper Sandler cut their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.